{"database": "lobbying", "table": "lobbying_activities", "rows": [[2460477, "1e662230-e357-4131-b70c-648ba5367ac6", "Q2", "WEXFORD SOLUTIONS LLC", 401104992, "OMNICELL 340B (FKA: PSG LLC)", 2020, "second_quarter", "HCR", "Discuss importance of 340B drug discount program and policy matters related to the program.", null, 20000, null, 0, 0, "2020-06-30T15:26:26.657000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2460477"], "units": {}, "query_ms": 128.52489901706576, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}